Schizophrenia Clinical Trials in St Louis, Missouri
6 studies are recruiting for schizophrenia in St Louis, Missouri right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
52-week Open Label Safety-Tolerability Study
Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia
- Stage
- Phase 3
- Ages
- 18 to 65
- Site
- Arch Clinical Trials, St Louis, Missouri
- Locations
- 23 in total
- Run by
- LB Pharmaceuticals Inc.
-
A Study of Brenipatide in Adult Participants With Schizophrenia
The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…
- Stage
- Phase 2
- Ages
- 18 to 55
- Site
- Arch Clinical Trials, St Louis, Missouri
- Locations
- 103 in total
- Run by
- Eli Lilly and Company
-
Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia
- Stage
- Phase 2
- Ages
- 18 to 65
- Site
- Arch Clinical Trials LLC, St Louis, Missouri
- Locations
- 16 in total
- Run by
- Novartis Pharmaceuticals
-
Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.
- Stage
- Phase 3
- Ages
- 18 to 65
- Site
- Arch Clinical Trials, St Louis, Missouri
- Locations
- 13 in total
- Run by
- LB Pharmaceuticals Inc.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
- Stage
- Phase 3
- Ages
- 18 to 65
- Site
- Neurocrine Clinical Site, St Louis, Missouri
- Locations
- 57 in total
- Run by
- Neurocrine Biosciences
-
Randomized Withdrawal Study in Patients With Schizophrenia
The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.
- Stage
- Phase 3
- Ages
- 18 to 65
- Site
- Vanda Investigational Site, St Louis, Missouri
- Locations
- 22 in total
- Run by
- Vanda Pharmaceuticals
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.